Y-box binding protein 1 pseudogene 9Genealiases: []
Q-omics provides the consensus-scored YBX1P9 profile across patient tissues and cancer cell-line models. YBX1P9 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, YBX1P9 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, YBX1P9 RNA expression shows 6,419 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, THCA, and STAD as cancer lineages where YBX1P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YBX1P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YBX1P9 survival associations across molecular data types. YBX1P9 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YBX1P9 RNA expression–survival associations across cancer types. High YBX1P9 expression shows unfavorable associations in UVM, READ, KICH, DLBC and STAD, but favorable associations in ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for YBX1P9 RNA expression.
This table summarizes YBX1P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for YBX1P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YBX1P9 shows lower tumor expression in THCA and higher tumor expression in KIRC. The THCA box plot shows higher YBX1P9 RNA expression in normal versus tumor tissue (log2 FC = −0.018, t-test p = .049).
This table shows molecular features associated with YBX1P9 in patient tissues and cancer cell lines. In patient samples, YBX1P9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
